@article{3088903,
    title = "Possible implication of IKAROS gene deletion and BCR-ABL1 variants in progression of chronic myeloid leukemia to lymphoid blast crisis in childhood: A single-institution experience",
    author = "Moschovi, M. and Adamaki, M. and Athanasiadou, A. and Divane, A. and Karytianou, A. and Tourkantoni, N.",
    journal = "Clinical Lymphoma Myeloma and Leukemia",
    year = "2015",
    volume = "56",
    number = "8",
    pages = "2460-2462",
    publisher = "Taylor and Francis Ltd.",
    doi = "10.3109/10428194.2014.999331",
    keywords = "BCR ABL 1 protein;  BCR ABL protein;  Ikaros transcription factor;  imatinib;  immunoglobulin heavy chain;  Janus kinase;  recombinase;  STAT protein;  transcription factor PAX5;  unclassified drug;  antineoplastic agent;  BCR ABL protein;  Ikaros transcription factor;  protein kinase inhibitor, acute lymphoblastic leukemia;  blast cell crisis;  bone marrow;  cancer growth;  cell maturation;  childhood leukemia;  chronic myeloid leukemia;  copy number variation;  DNA binding;  DNA repair;  EBF1 gene;  fluorescence in situ hybridization;  fusion gene;  gene;  gene deletion;  gene dosage;  gene rearrangement;  genetic variability;  human;  IKAROS gene;  IKZF1 gene;  Letter;  leukemia relapse;  leukemia remission;  minimal residual disease;  multiplex ligation dependent probe amplification;  PAX5 gene;  pre B lymphocyte;  priority journal;  real time polymerase chain reaction;  signal transduction;  T lymphocyte receptor gene;  blast cell crisis;  case report;  child;  disease course;  drug resistance;  female;  genetic variation;  genetics;  Leukemia, Myelogenous, Chronic, BCR-ABL Positive;  pathology;  treatment outcome, Antineoplastic Agents;  Blast Crisis;  Child;  Disease Progression;  Drug Resistance, Neoplasm;  Female;  Fusion Proteins, bcr-abl;  Gene Deletion;  Genetic Variation;  Humans;  Ikaros Transcription Factor;  Imatinib Mesylate;  Leukemia, Myelogenous, Chronic, BCR-ABL Positive;  Protein Kinase Inhibitors;  Treatment Outcome"
}